Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors.
Le Moing V, Chêne G, Carrieri MP, Besnier JM, Masquelier B, Salamon R, Bazin C, Moatti JP, Raffi F, Leport C; APROCO Study Group. Le Moing V, et al. Among authors: salamon r. J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):372-6. doi: 10.1097/00126334-200108010-00007. J Acquir Immune Defic Syndr. 2001. PMID: 11468425
Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study.
Lewden C, Raffi F, Cuzin L, Cailleton V, Vildé JL, Chêne G, Allavena C, Salamon R, Leport C. Lewden C, et al. Among authors: salamon r. J Infect Dis. 2002 Sep 1;186(5):710-4. doi: 10.1086/342047. Epub 2002 Jul 29. J Infect Dis. 2002. PMID: 12195361 Clinical Trial.
Is long-term virological response related to CCR5 Delta32 deletion in HIV-1-infected patients started on highly active antiretroviral therapy?
Laurichesse JJ, Taieb A, Capoulade-Metay C, Katlama C, Villes V, Drobacheff-Thiebaud MC, Raffi F, Chêne G, Theodorou I, Leport C; ANRS C08 Aproco-Copilote Study Group. Laurichesse JJ, et al. HIV Med. 2010 Apr;11(4):239-44. doi: 10.1111/j.1468-1293.2009.00769.x. Epub 2009 Dec 28. HIV Med. 2010. PMID: 20050936 Free PMC article.
Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial Group.
Pueyo S, Salmi LR, Chêne G, Leport C, Morlat P, Dequae L, Grégoire V, Hafner R, Vildé JL, Luft BJ, Aubertin J, Salamon R. Pueyo S, et al. Among authors: salamon r. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):459-64. doi: 10.1097/00042560-199704150-00010. J Acquir Immune Defic Syndr Hum Retrovirol. 1997. PMID: 9170421
Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group.
Leport C, Chêne G, Morlat P, Luft BJ, Rousseau F, Pueyo S, Hafner R, Miro J, Aubertin J, Salamon R, Vildé JL. Leport C, et al. Among authors: salamon r. J Infect Dis. 1996 Jan;173(1):91-7. doi: 10.1093/infdis/173.1.91. J Infect Dis. 1996. PMID: 8537688 Clinical Trial.
312 results